U.S. District Judge has given preliminary approval to three settlements.
U.S. District Judge Mitchell Goldberg has just given preliminary approval to three settlements between consumers and health plans and defendants Teva (which acquired defendants Cephalon and Barr), Mylan and Ranbaxy These settlements, totaling $65.87 million, when finally approved, will resolve the long–running Provigil litigation for end-payors. SRK, as co-lead counsel, will now begin the process of sending notice to class members. Consumers and health plans will have until December 6, 2019 to exclude themselves from the settlements, and until January 15, 2020 to object or file a claim. The Court will hold a final approval hearing on February 26, 2020 in Philadelphia. Stay tuned for updates. For more information, contact lead attorney John Macoretta at 215-496-0300 or email@example.com.